NAD+ Benefits: What Was Measured, and When
The substitution happens early and quietly: a finding about a swallowed precursor is reported as a finding about the thing in the bag.
Most lists of NAD+ benefits contain a substitution that happens before the first bullet point. The evidence being summarised comes largely from trials of precursors taken by mouth, and the product being sold is an infusion of the coenzyme itself. Sorting the claims by which intervention was actually tested does more work than sorting them by how impressive they sound, so that is where this starts.
Where the order actually gets placed
Ascension Peptides, NAD+
US-based and third-party tested. Enter the code on the payment step and the vial halves before you confirm.
Quoted per 100 mg because NAD+ is dosed in hundreds of milligrams, not the single milligrams a peptide vial holds. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Two batch certificates per lot
- Shipping free over $250
- Out the door same day if you order before 2pm CST
Everything here is research material for laboratory use, not for human consumption. Affiliate links, so we may earn a commission at no cost to you. Prices last checked August 20, 2026.
Reading the NAD+ benefits list by intervention rather than by claim
| Claim | Intervention actually tested | Organism | What was measured |
|---|---|---|---|
| Raises the level in the body | Oral nicotinamide riboside | Humans | Concentration in whole blood |
| Supports mitochondrial function | Precursors, and cell work | Cells and rodents | Enzyme activity and metabolic markers |
| Slows features of ageing | Oral precursors | Aged mice | Metabolic and functional measures in animals |
| Supports DNA repair | Cell and rodent work | Cells and rodents | Activity of repair enzymes |
| More energy, sharper thinking | Neither, in any published outcome trial | No organism | Nothing that was recorded |
| Recovery and detoxification by drip | Injected coenzyme | Not established in published outcome work | Not established |
Read down the second column rather than the first and the shape of the field appears immediately. One row has a human result. Two rows have animal and cell results. Two rows have nothing at all, and the row that describes what the clinics actually sell is the emptiest of the six.
The one finding that is solid, and why it is a biomarker
Oral nicotinamide riboside raises NAD+ measured in blood in human participants. That result has held up across separate trials, and it should be stated plainly rather than hedged, because a page that denies the good evidence loses the right to be believed about the bad.
What it is, though, is a biomarker result. It says the intervention did the biochemical thing it was designed to do. A blood concentration moved. Nobody got up from a chair faster, remembered more names or lived longer as part of that measurement, because those were not the endpoint.
This is a familiar pattern in metabolic research, and it fails often. A marker responds, the outcome does not follow, and the mechanism turns out to have been an incomplete account of the problem. Treating a confirmed biomarker shift as a confirmed benefit is the single most common error in writing about this compound, and it is made by people who are quoting real studies accurately.
Three objections worth answering here rather than at the end
If the level goes up, why would that not help?expand_more
Does a large research literature not count for something?expand_more
Are the animal results not encouraging?expand_more
Why does the infusion have so little behind it?expand_more
The order the claims were assembled in, which is backwards
There is a normal order for this kind of thing. Somebody observes a problem, proposes a mechanism, tests the mechanism in cells, tests it in animals, tests an intervention in people against a comparator, and if it survives all of that, a claim is made.
The claims in the table above did not arrive that way. They were assembled from the middle outwards. The mechanism came first and was genuinely interesting: an important coenzyme, consumed by important enzymes, at concentrations that fall with age in rodent tissue and in some human tissue analyses. From that middle point the argument ran forwards into promises and backwards into a product, and the trial stage that normally sits between the two was skipped for the injected form and only partly completed for the oral one.
You can see the consequence in how the benefits are phrased. They are almost all mechanism words wearing outcome grammar. Supports cellular energy production is a statement about a pathway. Feels like more energy is a statement about a person. The first is defensible and nearly content free. The second would need a trial. Marketing copy tends to place them in the same sentence, and the reader carries the confidence of the first across to the second without noticing the join.
Where the injected form sits, and why the gap is not a technicality
It would be convenient if the infusion were simply a faster version of the capsule. It is not, and the difference is chemical rather than administrative.
Cells are equipped to take up the small precursors. The assembled coenzyme is a larger, charged molecule, and enzymes on the outside of cells break it down. What proportion of an infused quantity ends up doing anything inside a cell, as opposed to being dismantled first, is an open pharmacological question rather than a rounding error. That is why a precursor trial cannot be quoted as support for a drip without a bridging argument nobody has published.
Until that bridge exists, every benefit in the table above that was measured with a precursor belongs to the precursor. Moving it across is not a small liberty. It is the entire claim.
There is a second reason the gap should not be waved away, and it concerns dose. An oral precursor is taken in a quantity a gut can absorb over hours, repeatedly, over weeks. An infusion delivers a large quantity of a different molecule directly into the circulation over a couple of hours, on a handful of occasions. Even if the two ended up raising the same internal quantity, they would not be raising it in the same pattern, and a pathway that runs continuously may well respond differently to a steady nudge than to an occasional flood. Nobody has published the comparison, so this remains a reason for caution rather than a finding.
The claims with no measured origin at all
Two of the six rows have nothing behind them in either intervention, and they happen to be the two that sell.
Energy and mental clarity are the headline promises of infusion clinics. They correspond to no published endpoint in any organism for this compound. That is a stronger statement than unproven, which implies somebody tried. Nothing was measured, so there is nothing to be unproven.
The recovery and detoxification claims sit in the same position. They are supported by clinic testimonials and by practitioner report, and those are a description of what people believe happened rather than a record of what did. An infusion is a long, physically noticeable, expensive event attended by staff, which is close to a perfect setup for expectation to produce exactly the feeling being advertised.
What would move any of these into a stronger category
The requirement is not complicated and it is not being met.
For the injected form, it would take a registered trial with a comparison group, a pre-specified outcome that matters to a person rather than a level in a tube, an assessment made by someone who does not know who got what, and results published whichever way they came out. Blinding is the hard part with an infusion, since the sensation is distinctive, but a comparator infusion is not impossible to design.
For the precursors, the next step is different. The biomarker question is answered. What remains is whether the raised level produces an outcome, which needs longer trials with harder endpoints, and several of those are the sort of thing that takes years rather than months.
Neither of those has to happen for a clinic to keep selling appointments, which is the honest reason to expect the current state of affairs to persist.